You are here

  • Home
  • Archive
  • Volume 62, Issue 9
  • Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis

Article Text

Article menu
Download PDFPDF
Letter
Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis
  1. I Foeldvari1,
  2. E Krüger2,
  3. T Schneider2
  1. 1Paediatric Rheumatology Clinic at AK-Eilbek, 22081 Hamburg, Germany
  2. 2Paediatric Clinic, LBK-Klinikum Heidelberg, 22417 Hamburg, Germany
  1. Correspondence to:
    Dr I Foeldvari, Paediatric Rheumatology Clinic at AK-Eilbek, Friedrichsberger Str 60, D-22081 Hamburg, Germany;
    sprechstunde{at}kinderrheumatologie.de

https://doi.org/10.1136/ard.62.9.908

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Etanercept and infliximab are soluble tumour necrosis factor α (TNFα) antibodies. Etanercept is approved for the treatment of polyarticular juvenile rheumatoid arthritis (JRA), and infliximab is in the process of being approved. We report the first case in which the same patient developed a non-obstructive, sterile cholecystitis with etanercept (Enbrel) and later with infliximab (Remicade).

    CASE REPORT

    A 15 year old white female patient with polyarticular JRA, treated with a combination of 14 mg/m2 methotrexate once a week intramuscularly and 2 g sulfasalazine a day, did not show any …

    View Full Text